Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

about

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

P2860

Q46240322-08C53228-65C4-4D5B-81E2-5646BD32FE60

P2860

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Item

http://www.wikidata.org/entity/Q43531574

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@en

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@nl

type

Item

label

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@en

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@nl

prefLabel

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@en

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@nl

P1476

Toxicity, pharmacokinetics and ...... IL-6-induced STAT3 activation.

@en

P2093

Brian F Kiesel

http://www.w3.org/2001/XMLSchema#string

Jianxia Guo

http://www.w3.org/2001/XMLSchema#string

Julie L Eiseman

http://www.w3.org/2001/XMLSchema#string

Raffaele Colombo

http://www.w3.org/2001/XMLSchema#string

Robert A Parise

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors

Cancer statistics, 2015

Stat3 as an oncogene

Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors

HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines

High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

First-pass elimination. Basic concepts and clinical consequences.

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism.

STAT3 signaling: anticancer strategies and challenges.

Species differences in N-glucuronidation.

P2888

s00280-016-3181-9

P304

1225-1235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3181-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036601741

http://www.w3.org/2001/XMLSchema#string

P698

27778071

http://www.w3.org/2001/XMLSchema#string

P932

5115981

http://www.w3.org/2001/XMLSchema#string

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

about

P2860

P2860

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932